Dr. Reddy’s Shares in Spotlight After USFDA Observations.

Dr. Reddy’s Laboratories will be closely watched in the market on July 21, following a regulatory development from the United States Food & Drug Administration (USFDA). What happened? USFDA conducted a GMP (Good Manufacturing Practices) and Pre-Approval Inspection (PAI) at Dr. Reddy’s FTO 11 formulations facility in Srikakulam, Andhra Pradesh. 📅 Inspection dates: July 10–18, 2025 Following the inspection, USFDA issued a Form 483 with 7 observations. These are procedural or quality-related issues found during inspection — not uncommon in pharma — and the company has stated it will address them within the prescribed timeline. What’s next? Dr. Reddy’s is also scheduled to announce its Q1 FY26 results on July 23, 2025, after its board meeting. Summary: • Facility: FTO 11, Srikakulam (Andhra Pradesh) • Inspection Outcome: 7 observations in Form 483 • Next Event: Q1 results on July 23 Investors will track both the company’s response to USFDA and its earnings outcome next week. Any update on resolution of observations or positive result commentary could influence the stock movement ahead. Please follow for daily stock market insights.